A Randomized, Double-Blind, Multicenter, phase III Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan (BR-A-657-K) 30mg Compared to Placebo in Patients with Mild to Moderate Essential Hypertension
Phase of Trial: Phase III
Latest Information Update: 25 Aug 2016
At a glance
- Drugs Fimasartan (Primary) ; Valsartan
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Boryung
- 30 Jun 2016 Status changed from recruiting to completed.
- 24 Aug 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01672476).
- 24 Aug 2012 Planned End Date 1 Mar 2013 added as reported by ClinicalTrials.gov.